reason report
dupix expand expens competit threat eylea
grow pt
bottom line reiter outperform rate
lower price target morn regeneron report
result beat consensu total revenu
consensu line estim pro-forma ep
consensu estim eylea
consensu upsid came stronger dupix
collabor revenu expens lower expect
gross margin come product sale oper margin
hold rang tax rate even lower
expect result ep beat free cash flow
approxim sale total cash stand
although compani revenu still grow
yoy profit steadili improv investor
increasingli look longev eylea revenu outlook given
near term prospect competitor enter intravitr
vegf categori next two year see compani growth
stori larg intact dupix way revenu
label expans underway come mani
increment revenu opportun open compani libtayo
solid tumor eylea diabet retinopathi etc howev expens
new trial new molecul new indic new promot tactic
continu increas well adjust model account
continu growth commerci invest partner
wholly-own drug increas mean partnership break-even
still year away could even longer depend
cost major launch asthma
multipl upcom regulatori approv open increment
revenu opportun next month regeneron
expect fda approv dupix adolesc atop dermat
ad praluent cardiovascular outcom data eylea diabet
retinopathi dr eylea pre-fil syring outsid us
compani also benefit eu approv dupix asthma
libtayo cutan squamou cell carcinoma cscc addit
later week american heart associ announc
new lipid treatment guidelin nov potenti formal
incorpor antibodi treatment recommend follow
consensu recommend focus updat updat
could potenti lessen payer resist use drug
averag price-to-earnings p/ dcf
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu mm dilut ep non-gaap
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
could particularli favor praluent recommend
specifi certain patient popul high
treat class drug import readout pivot studi
includ phase result libtayo basal cell carcinoma
confirm call long-term safeti result fasinumab
osteoarthr emerg product candid expect
efficaci data present bispecif antibodi
cell malign dose-rang data antibodi pozelimab
healthi volunt upcom american societi hematolog
lp revenu forecast lower eylea praluent pt
given increas confid least one
come market next year dial
back forecast eylea global sale account potenti
competit us eylea sale forecast unchang
decreas ou eylea number
decreas given soften trend
see new entrant captur growth
opportun expens eylea growth increas
estim dupix period base
expect deepen penetr atop dermat expans
indic lower forecast praluent
reflect effect fall price rel
slow categori growth result revenu forecast regeneron
increas decreas
year remain recent consensu
consensu estim oper margin
higher lower year increas non-gaap
ep forecast decreas ep estim
ep forecast remain recent
consensu base chang estim chang
peer compani multipl price target come
reiter outperform rate
previous cover highlight regeneron
confer call recap note link
price target regeneron stock rate outperform regeneron
veteran biopharmaceut compani come initi base portfolio fast-
follow second entrant rapidli grow biopharmaceut market first product eylea
continu surpris investor taken grown market intraocular
vegf vascular endotheli growth factor antibodi treatment eylea contribut nearli
global sale trump categori pioneer roch lucenti well
cheaper altern compound bevacizumab remain posit eylea expect
continu grow lose market share emerg competitor
novarti seem like approv excit aspect
compani next wave innov antibodi notabl dupix approv
adult atop dermat like receiv label expans multipl allerg diseas
indic expect dupix dupilumab gener revenu
signific upsid indic longer term regeneron wholli own
antibodi could contribut meaning revenu earn growth
period current compani invest mode result earn cash flow
convers revenu lag peer industri anticip cash flow true
earn improv period profit antibodi collabor
sanofi begin accumul
revenu beat in-lin us eylea stronger collabor revenu total
revenu consensu line estim
regeneron report global eylea sale consensu
number us sale eylea line consensu
estim ex-u eylea sale
consensu estim estim result sanofi
collabor product previous disclos last tuesday sanofi varianc
consensu estim alreadi anticip market dupix sale
consensu estim praluent sale
consensu forecast total collabor revenu
regeneron partnership sanofi bayer teva quarter
consensu in-line estim reflect higher expect eylea
dupix profit share off-set lower sanofi reimburs higher dupix
lower expens tax rate drive ep beat regeneron report total non-gaap
oper expens consensu estim
beat primarili occur cog sg expect
well regeneron also report lower tax rate compar consensu
forecast combin two item help deriv pro forma ep result
consensu estim
guidanc updat lower expens tax regeneron updat element
guidanc previous provid includ expens tax capit expenditur
regeneron lower non-gaap unreimburs guidanc
lower non-gaap sg guidanc
total sanofi reimburs commerci relat expens also lower
previous regeneron also expect effect tax rate
rang lower compar previous compani lower guidanc
capit expenditur reduct regeneron intern
expens lower top-end rang sanofi commerci expens
view posit investor increasingli focus compani top-lin
challeng less disciplin oper margin manag
eylea maintain lead posit growth opportun diabet retinopathi dr
eylea sale grew yoy sequenti us maintain
brand anti-vegf market modest sequenti decreas inventori greater overal
product discount regeneron continu bullish revenu opportun ahead
diabet eye diseas posit top-line result report recent pdufa
date dr may increas awar regeneron launch direct-to-consum
advertis campaign eylea plan initi anoth focus campaign larg
untap dme popul recent fda approv dose schedul
regeneron manag express confid competit posit
includ novarti manag argu claim advantag
dose schedul good appear paper patient
elig dose actual maintain dose schedul rais
issu higher rate ocular inflamm trial compar eylea
ad physician patient quit sensit risk inflamm despit
surpris sbla eylea pre-fil syring manag comment still
track potenti launch syring formul upon expect submiss
supplementari data bla call regeneron also state higher-dos
formul eylea expect enter clinic potenti either increas efficaci
extend dose interv although manag provid detail guidanc
eylea sale see chang underli demograph age popul
higher incid diabet underpenetr treatment immin disrupt
competitor even though regeneron acknowledg possibl novarti roch
enter market time-frame reason overal anti-vegf market
grown accommod player
dupix volum growth slow soon fuel label expans
dupix volum growth increas compar percentag point
lower sequenti growth report put product full year
sale run rate base comment regeneron sanofi manag
atop dermat ad patient dose far dupix
regeneron sanofi target popul adult patient us prescrib
sponsor continu add steadi new patient per week treatment treatment
persist stabil around one month one year manag
comment number patient current drug lower number total
initi may amount adult preval pool suggest still
major elig adult ad market penetr competition-fre period
regeneron estim adolesc ad preval half adult
believ uptak adolesc ad patient similar slightli faster
adult popul given physician experienc dupix
greater perceiv sever diseas young patient popul follow-up
convers manag regeneron comment payer appear lenient
manag biolog asthma although formulari manag
among antibodi payer still leav room class anti-ig
regeneron view fact dupix fall pharmaci benefit categori
eventu advantag allow payer better visibl expens abil
track usag manag class compani provid color price
dupix asthma given earli stage launch expect net price dupix
vs becom major topic among analyst investor
oper margin improv trend discuss trend oper expens
manag gross margin quarter result mix on-going trend one-
time variat seem like go manag also comment
current expens rate sg starv busi still room
increas follow quarter support campaign direct-to-consum
commerci eylea dupix regard expect time break-even
collabor sanofi regeneron sound less definit sanofi expect
collabor turn profit provid clear timelin break-even
profit signific futur leverag term tax rate manag comment
rate see quarter benefit mani one-tim item expect tax rate next
year rang mid- high teen
pipelin extens come fruition multipl upcom regulatori approv
regeneron expect fda approv dupix adolesc ad pdufa date
fda approv praluent cardiovascular outcom data pdufa date apr
fda approv eylea dr pdufa date may fda approv
eylea pre-fil syring follow re-submiss outsid us
compani benefit approv dupix asthma eu libtayo
cutan squamou cell carcinoma eu addit later week american
heart associ announc new lipid treatment guidelin nov
potenti formal incorpor antibodi treatment recommend follow
consensu recommend focus updat updat could potenti lessen
payer resist use could particularli favor praluent
recommend specifi certain patient popul high treat
class drug import readout pivot studi includ phase result libtayo
basal cell carcinoma confirm call long-term safeti result
fasinumab osteoarthr emerg product candid expect efficaci
data present bispecif antibodi cell malign dose-rang
data antibodi pozelimab healthi volunt upcom meet
price target regeneron base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar high growth larg molecul biopharmaceut compani price
sale multipl larg cap high growth compani discount cash flow dcf use
averag larg cap larg molecul therapeut compani nvo
nv earn multipl ep appli current ep estim
give valu use high growth revenu multipl similar compani
nvo consensu sale appli
revenu estim give valu lastli dcf valuat given
wacc termin cash flow growth rate give present valu averag
three method current price target
risk view outlook valuat regeneron includ major chang price
reimburs coverag label competit posit eylea compani main
product today risk includ commerci develop disappoint compani
next partner program launch dupix kevzara well continu weak
demand compani cholesterol treatment praluent subsequ releas
cardiovascular outcom data regeneron fail match cardiovascular outcom
demonstr rival product would advers affect
revenu outlook valuat lastli compani convert rel littl
revenu cash flow today histori return cash investor ultim
may undermin valu stock investor willing continu
sale
collabor
share count period dilut mm
guidanc
tax non-gaap pre-tax incom
sanofi reimburs regeneron
leerink partner research compani file zack factset consensu
collab manufactur
leerink partner research compani file zack factset consensu
time event
present
fda approv adolesc patient
fda approv cv outcom data
fda re-submiss pre-fil syring
phase result follow safeti
leerink partner research compani report present clinicaltri gov
late stage pipelin program includ
late stage pipelin program exclud
eylea dr w/o dme
nsclc basal cell
million
leerink partner research compani file
million
good sold
research develop
sell gener administr
collabor manufactur
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink partner target regeneron
method high growth larg cap growth biotech ep multipl
ep nvo nv azn rhhbi
leerink partner forma ep estim
impli price ep
equiti
number period
method larg cap biopharma forward multipl enu
discount
larg cap high growth biopharma price/sal multipl
leerink partner revenu forecast
impli ev revenu
share count
ev per share
expect net per share
net expect valu per share
equiti
number period
impli share price
present valu po adjust flow
pv termin valu
net
share count
averag method
leerink partner research compani file factset
